Severe Precapillary Pulmonary Hypertension Due to Whipple Disease
Abstract
Background: Whipple disease (WD), a rare systemic infection caused by Tropheryma whipplei, represents an uncommon but recognized cause of reversible pulmonary hypertension (PH).
Case summary: A 41-year-old woman with a history of arthritis, eczema, and low-grade fever was referred to our center with severe precapillary PH. Initial diagnostic work-up suggested sarcoidosis, prompting initiation of immunosuppressive therapy. Shortly thereafter, the patient developed severe diarrhea. Subsequent colonoscopy and intestinal biopsy revealed WD. After the initiation of targeted antibiotic therapy, the patient experienced rapid clinical improvement, with complete resolution of symptoms and normalization of hemodynamic parameters.
Discussion: This case demonstrates that systemic inflammation in WD can involve the pulmonary vasculature and lead to precapillary PH, which may be fully reversible with timely diagnosis and targeted antibiotic therapy.
Take-home message: PH is a pathophysiological condition defined by elevated mean pulmonary arterial pressure arising from primary pulmonary vascular disorders or as a consequence of other conditions such as WD.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.